Daniel Drucker, MD, then a postdoctoral fellow in the Habener lab, characterized the enzymatic activity of GLP-1, while Jens Juul Holst, MD, at the University of Copehagen, simulatenously discovered GLP-1 regulated insulin secretion
On April 1, 2026, the FDA issued a significant policy clarification targeting the most common remaining workaround: compounders and telehealth providers had been adding a secondary ingredient most commonly vitamin B12 to their semaglutide formulations and marketing them as distinct, patient-specific products not subject to the "essentially a copy" prohibition
The same goes for fiber-spiked products like Superguts Natures Ozempic prebiotic powder and bars
According to the FDA, GLP-1 weight loss medications are indicated for adults with a body mass index (BMI) of 30 or greater, or for adults with a BMI of 27 or greater who also have at least one weight-related health condition such as hypertension, type 2 diabetes, or high cholesterol
Key takeaways Contrave is a brand-name prescription weight loss medication